Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03614923 · ClinicalTrials.gov registry record · Phase 2

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

A Phase 2 study of Chronic Rhinosinusitis, sponsored by AnaptysBio.

Completed
Registry status
Phase 2
Development phase
105
Enrollment target
20
Study locations

NCT03614923 is a Phase 2 study of Chronic Rhinosinusitis that has completed, run by AnaptysBio. The registered enrollment target is 105 participants, below the 164-participant average among 4 other Chronic Rhinosinusitis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03614923, a Phase 2 study of Chronic Rhinosinusitis, has completed, sponsored by AnaptysBio.

COMPLETED
Registry status
Phase 2
Development phase
105 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Etokimab
  • DRUG Mometasone Furoate Nasal Spray

Study Locations (20)

California

  • Alliance Research Institute - Canoga Park
  • DaVinci Research - Roseville
  • Sacramento Ear Nose and Throat Surgical and Medical Group Inc. - SacENT - Sacramento
  • Allergy & Asthma Medical Group and Research Center - San Diego

Oklahoma

  • Allergy Asthma Clinical Research Center - Oklahoma City
  • Allergy Asthma and Immunology Center P.C. - Tulsa
  • Central States Research, LLC - Tulsa

Florida

  • Intermed Medical Research Center - Miami
  • Advanced Research Institute, Inc. - New Port Richey

North Carolina

  • University of North Carolina Hospitals - Chapel Hill
  • Charlotte Eye Ear Nose and Throat Associates - Matthews

Arkansas

  • Asthma & Allergy Institute - Little Rock

Colorado

  • Colorado Allergy Asthma Centers - Denver

Georgia

  • Clinical Research Consultants of Atlanta - Suwanee

Idaho

  • Treasure Valley Medical Research - Boise

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2018-11-29
Est. Completion 2020-10-26
Phase Phase 2

Sponsor

AnaptysBio

7 total trials

What the Registry Record Tells You About NCT03614923

The ClinicalTrials.gov registry entry for NCT03614923 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 4 other Chronic Rhinosinusitis trials with a reported enrollment target (36% lower). The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Rhinosinusitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03614923 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Oklahoma, Florida.

Frequently Asked Questions

What is clinical trial NCT03614923 about?

NCT03614923 is a clinical study titled "Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)". A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.

What is the current status of trial NCT03614923?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2018-11-29. Estimated completion is 2020-10-26.

What conditions does trial NCT03614923 study?

This clinical trial studies the following conditions: Chronic Rhinosinusitis.

What interventions are being tested in trial NCT03614923?

The interventions under investigation include: Placebo (BIOLOGICAL), Etokimab (BIOLOGICAL), Mometasone Furoate Nasal Spray (DRUG).

Who is sponsoring clinical trial NCT03614923?

This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03614923 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Rhinosinusitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.